HEMATOLOGY

David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, explains the significance of the initial results from a recent phase 1B/2 trial combining APR-246 and azacitidine (Vidaza) in patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.

Karyopharm Therapeutics has announced that a rolling submission of an FDA new drug application has been completed for selinexor as a treatment for patients with penta-refractory multiple myeloma, based on results from part 2 of the phase IIb STORM trial.

Julie M. Vose, MD, MBA, Chief in the Division of Oncology/Hematology at the University of Nebraska Medical Center, discusses strategies for overcoming resistance in lymphoma during the 2018 Pan Pacific Lymphoma Conference. 

Mogamulizumab-kpkc (Poteligeo) has been approved by the FDA as a treatment for patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

Targeted Treatment for IDH2-Mutated AML

Danielle Brander, MD, highlights how recent advances are changing the field of CLL and what it means for physicians and their patients.

Brad S. Kahl, MD, professor in the department of medicine at Washington School of Medicine at Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in older patients with mantle cell lymphoma. This agent is currently being investigated in the frontline setting for patients not eligible for stem cell transplant.

Guadecitabine failed to improve complete response rate and overall survival in treatment-naïve adult patients with AML who are not candidates for intensive induction chemotherapy, missing the coprimary endpoints of the phase III ASTRAL-1, according to Astex Pharmaceuticals and Otsuka Pharmaceutical.

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the results from 2 large phase III trials presented earlier this year for triplet regimens including pomalidomide in multiple myeloma.

Quizartinib has been granted a breakthrough therapy designation by the FDA&nbsp;for the treatment of adult patients with relapsed/refractory&nbsp;<em>FLT3</em>-ITD&ndash;positive acute myeloid leukemia.

The FDA issued several approvals in July, including in colorectal cancer, breast cancer, prostate cancer, and acute myeloid leukemia.&nbsp;Here&rsquo;s a look back on the FDA happenings for the month of July 2018.

Susan M. O&#39;Brien, MD, associate director for clinical sciences at UC Irvine Health, shares her insights on why CAR T cells are not as successful in chronic lymphocytic leukemia as compared to lymphoma or acute lymphocytic leukemia. She also discusses what she believes must change in order for this therapy to move up in the treatment landscape for CLL.

In an interview with&nbsp;<em>Targeted Oncology</em>, Paul G. Richardson, MD,&nbsp;clinical program leader and director of Clinical Research in the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute,&nbsp;discussed the results from the OPTIMISMM trial. He also shared his insight on the significance of these findings and what he expects to see in the future for this patient population.

Jacqueline D. Barrientos, MD, MS,&nbsp;discusses the current treatment landscape for CLL. She also highlights some of the biggest challenges for physicians and gave her insight on how to move forward in the field.

The R² regimen of lenalidomide (Revlimid) with&nbsp;rituximab (Rituxan) significantly improved progression-free survival compared with&nbsp;rituximab monotherapy in the&nbsp;treatment of patients with relapsed/refractory indolent lymphoma, meeting the primary endpoint of the phase III AUGMENT trial, Celegene,&nbsp;the manufacturer of lenalidomide, has announced.

Anthony R. Mato, MD, MSCE,&nbsp;discusses the next steps for umbralisib and the biggest challenges still facing patients with CLL.

Daniel A. Pollyea, MD, MS, associate professor of medicine&nbsp;and clinical director of Leukemia Services at the University of Colorado&nbsp;School of Medicine, discusses some of the recent advancements in acute myeloid leukemia. Pollyea says researchers have been able to create more personalized treatments for many patients by doing targeted sequencing of patient samples.